Back to search

Article

Efficacy and Safety of Bevacizumab-Combined Single-Agent Chemotherapy for Platinum-Resistant Ovarian Cancer that Recurred During PARP Inhibitor Treatment

2025-11-06

Abstract excerpt

<title>Abstract</title> <p>Background Currently, there are no reports on the subsequent treatment of patients with ovarian cancer who exhibited platinum-resistant recurrence during treatment with poly(ADP-ribose) polymerase (PARP) inhibitors. This retrospective study was aimed at evaluating the efficacy and safety of single-agent chemotherapy combined with bevacizumab (BEV) in such patients. Patients and Methods...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a18e27b5-e1ee-5fe6-93f5-740548bbfa19
DOI
10.21203/rs.3.rs-7904976/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Efficacy and Safety of Bevacizumab-Combined Single-Agent Chemotherapy for Platinum-Resistant Ovarian Cancer that Recurred During PARP Inhibitor TreatmentDOI 10.21203/rs.3.rs-7904976/v1
Effects of PARP Inhibitors on Subsequent Platinum-Based Chemotherapy in Patients with Recurrent Ovarian CancerSemantic proximity
Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”Semantic proximity
PARP Inhibitors in Newly Diagnosed and Recurrent Ovarian CancerSemantic proximity
A real-world study of treatment patterns following disease progression in epithelial ovarian cancer patients undergoing poly-ADP-ribose polymerase inhibitor maintenance therapySemantic proximity
Molecular and clinical predictors of improvement in progression‐free survival with maintenance PARP inhibitor therapy in women with platinum‐sensitive, recurrent ovarian cancer: A meta‐analysisSemantic proximity
PARPis after PARPis in patients with recurrent epithelial ovarian cancer: A single institutional experienceSemantic proximity
Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer.Semantic proximity
PARP Inhibitors in Ovarian Cancer: Resistance Mechanisms, Clinical Evidence, and Evolving StrategiesSemantic proximity
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.Semantic proximity
Efficacy and safety analysis of PARP inhibitors combined with drugs for primary and relapsed ovarian cancer: A meta-analysis of randomized controlled trialsSemantic proximity
A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)Semantic proximity
Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.Semantic proximity
Select a neighboring publication to make it the new centre.